Latest Hotspot

Vigil Neuroscience: Phase 2 IGNITE trial shows promising early results for Iluzanebart (VGL101) in treating ALSP

28 November 2023
3 min read

Vigil Neuroscience, Inc., a company specializing in clinical-stage biotechnology, is dedicated to leveraging the potential of microglia for handling neurodegenerative diseases. The firm revealed promising preliminary results from their Phase 2 IGNITE proof-of-concept clinical trial, that is being conducted on patients suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The initial information, depicting the initial six patients after half a year's treatment of 20 mg/kg iluzanebart (formerly referred to as VGL101), reinforces the beneficial safety and tolerability track record, as already observed in healthy volunteers. Additionally, these figures highlighted definite target interaction and subsequent pharmacological movement at 20 mg/kg, in line with the company’s past Phase 1 information from fit volunteers. 

Beneficial trend changes were watched at half a year on magnetic resonance imaging and neurofilament light disease progression markers in unique ALSP patients. Ongoing findings from the Company's ongoing natural history examination, ILLUMINATE, continuously offer profound understanding into MRI and NfL biomarkers and backs soluble colony stimulating factor 1 receptor as a potential primary biomarker of ALSP disease pathology. 

"The findings reflect the commitment and proficiency of our exceptional crew, who bring an unshakeable commitment to patients to their duties," concluded Dr. Magovčević-Liebisch. "To everyone who aided this advancement, including our trial members, their caretakers, and the clinical examiners, we give our deepest gratitude. 

We anticipate revealing more information from the IGNITE trial, including results from all patients in both the 20 mg/kg and 40 mg/kg groups at half a year, in the third quarter of 2024."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 26, 2023, there are 1 investigational drugs for the Hereditary Diffuse Leukoencephalopathy With Spheroids, 1 R&D institutions involved, with related clinical trials reaching 11, and as many as 135 patents.

VGL-101 is intended to treat various conditions, including Hereditary Diffuse Leukoencephalopathy With Spheroids, Leukoencephalopathies, Alzheimer Disease, and Hair Defect With Photosensitivity and Mental Retardation. The drug has been designated as an Orphan Drug, indicating its potential to address rare diseases. Further research and regulatory processes are necessary to determine its effectiveness and safety.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

An analysis of Acimtamig's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
An analysis of Acimtamig's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
28 November 2023
On 11 Dec 2023, the latest clinical trial of Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas will be reported in 2023 ASH.
Read →
AskBio begins Phase 1 trial with first patient for their MSA-P gene therapy, AB-1005
Latest Hotspot
3 min read
AskBio begins Phase 1 trial with first patient for their MSA-P gene therapy, AB-1005
28 November 2023
AskBio reveals the enrollment of their initial patient into the Phase 1 trial for AB-1005 (AAV2-GDNF), their gene therapy solution to Multiple System Atrophy-Parkinsonian Type (MSA-P).
Read →
What are COX inhibitors and how do you quickly get the latest development progress?
What are COX inhibitors and how do you quickly get the latest development progress?
24 November 2023
The analysis of the target COX reveals a competitive landscape with several companies making progress in the development of COX inhibitors.
Read →
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
Latest Hotspot
3 min read
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
24 November 2023
Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.